Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Total Debt (2016 - 2025)

Sanofi (SNY) has disclosed Total Debt for 11 consecutive years, with $21.6 billion as the latest value for Q4 2025.

  • Quarterly Total Debt rose 26.57% to $21.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.6 billion through Dec 2025, up 26.57% year-over-year, with the annual reading at $21.0 billion for FY2025, 21.28% up from the prior year.
  • Total Debt hit $21.6 billion in Q4 2025 for Sanofi, up from $17.1 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $23.2 billion in Q4 2021 to a low of $17.1 billion in Q4 2024.
  • Historically, Total Debt has averaged $19.8 billion across 5 years, with a median of $19.4 billion in 2022.
  • Biggest five-year swings in Total Debt: fell 16.42% in 2022 and later grew 26.57% in 2025.
  • Year by year, Total Debt stood at $23.2 billion in 2021, then decreased by 16.42% to $19.4 billion in 2022, then fell by 9.17% to $17.6 billion in 2023, then decreased by 3.06% to $17.1 billion in 2024, then increased by 26.57% to $21.6 billion in 2025.
  • Business Quant data shows Total Debt for SNY at $21.6 billion in Q4 2025, $17.1 billion in Q4 2024, and $17.6 billion in Q4 2023.